Press Release: New Directors for Client Delivery and Business Development join Diligent Pharma
Princeton, New Jersey
April 22, 2021
Diligent Pharma LLC announced today it has appointed Tawala Taylor as Director of Client Delivery and George Parrish as Director of Business Development.
Tawala will manage the successful delivery of Diligent’s solutions and maintain strong relationships with Diligent’s clients across the clinical research sector.
Clinical trial sponsors, CROs, research sites, as well as clinical research service and technology providers around the world rely on Diligent to streamline the processes for selection and qualification of service providers. Tawala’s role will be to ensure the needs of these clients are being fulfilled by Diligent technology and services, which will require close collaboration with internal teams as well as client relationship management.
Tawala will also be responsible for engagement activities with Sponsors and Providers, along with review of the RFI (Request for Information) information and VQA (Vendor Qualification Assessment) reports in the Diligent Platform.
Tawala joins Diligent with over 15 years of experience in clinical research including a background in Quality Assurance auditing and vendor management. Most recently she has worked at Amgen/PRA Health Sciences and INC Research.
George Parrish also joined Diligent as Director of Business Development in the first quarter. George has worked in the life sciences sector for eight years at clinical services providers including Cmed, MMG and FDAnews delivering clinical data management, patient recruitment and regulatory compliance.
Commenting on the new appointments, Lee Jones, President of Diligent said, “We are delighted that Tawala and George have joined Diligent. We look forward to leveraging Tawala’s deep knowledge of the qualification process as our platform grows to serve more clients, as well as George’s experience of relationship building across a wide range of pharma and biotech organizations.”
Tawala is based in Chesapeake, Virginia and George works from Rockville, Maryland.
The Diligent Qualification Platform connects clinical research sponsors, CROs, technology and service providers to streamline and simplify the selection and qualification of clinical trial service providers.
The cloud-based Diligent Qualification Platform holds comprehensive Request for Information (RFI) details for over 80 industry suppliers as well as Vendor Qualification Assessments (VQAs) audited against latest industry standards. The platform makes this information available rapidly for trial sponsors in a controlled and confidential way. This makes it easy for trial sponsors to identify and qualify relevant potential suppliers so the Diligent Platform can reduce the time taken to start clinical trials by up to 70 days.
The Platform is offered by Diligent Pharma, LLC based in Princeton, NJ.
The Diligent platform will simplify and streamline your provider selection and qualification processes